ACTRN12619000427178尚未招募未知
Inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) for treatment of alcohol dependence - An open-label early phase safety and feasibility pilot study.
Hunter New England Health Drug and Alcohol Clinical Services0 个研究点目标入组 12 人开始时间: 2019年3月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1.Provide written, informed consent to participate in the study
- •2.Aged 18 to 65 years
- •3.Be treatment seeking for alcohol dependence
- •4.Meet DSM-5 criteria for moderate to severe alcohol use disorder (alcohol dependence) for at least twelve months
- •5.Self-report alcohol use of greater than or equal to 21 days out of the previous 28
- •6.Adequate liver function as shown by normal total bilirubin and albumin, ALT and AST less than or equal to 2.5 X upper limit of normal, INR less than or equal to 2
- •7.Adequate renal function, serum creatinine less than or equal to 1.5 X ULN
- •8.Patient must have adequate lipid profile, including fasting serum cholesterol, fasting glucose or fasting triglycerides
- •9.Full blood count and WBC differential within normal ranges
- •10.Adequate bone marrow function, including ANC and platelets
- •11.Females of child bearing potential must not be pregnant as confirmed by a negative pregnancy test (serum confirmed beta-hCG) or breastfeeding prior to study enrolment. Women of childbearing potential must agree to use adequate high-effective contraception for the duration of study participation and at least four months after the last dose of everolimus (e.g. oral contraception, intrauterine device, implant, combination of barrier methods, abstinence). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and 4 months after completion of everolimus administration.
- •12.Be willing and able to comply with requirements of study
排除标准
- •1.Plans for immediate residential treatment/rehabilitation post withdrawal
- •2.Antidypsotropic (acamprosate, naltrexone, disulfiram) pharmacological treatment for alcohol dependence for more than 7 days in the previous month
- •3.Plans to commence antidypsotropic pharmacological treatment (acamprosate, naltrexone, disulfiram) for alcohol dependence during the study (inclusive of treatment and follow-up period)
- •4.History of complicated/severe alcohol withdrawal (e.g. alcohol withdrawal seizures, delirium).
- •5.Patients with a known hypersensitivity to everolimus or other rapalogues (sirolimus, temsirolimus)
- •6.Contraindication to study drug (everolimus): Hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients
- •7.High or increasing C-reactive Protein, CRP levels =10mg/L
- •8.Systemic infection requiring therapy at study entry
- •9.Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. As lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx or medical reference text.
- •10.HIV-positive patients on combination antiretroviral therapy. These therapies have potential pharmacokinetic interactions with everolimus. Patients are also at increased risk of lethal infections when treated with marrow suppressive therapy.
- •11.Presence of another moderate-severe substance use disorder (other illicit or prescription drug dependence) with the exception of nicotine dependence, diagnosed by specialist clinical assessment against DSM-5 criteria, including urine drug screen. Already receiving study drug for any reason (e.g. kidney or cardiac allograft)
- •12.Patients who have had major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anaesthesia), or patients who may require major surgery during the course of the study.
- •13.Prior treatment with any investigational drug within the preceding 4 weeks.
- •14.Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent, except corticosteroids with a daily dosage equivalent to prednisone = 20 mg. Patients receiving these corticosteroids must have been on a stable dosage regimen for a minimum of 4 weeks prior to the first treatment with Everolimus. Topical or inhaled corticosteroids are allowed.
- •15.Patients who have received immunization with attenuated live vaccines within one week of study entry or during study period.
- •16.Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- •a.Symptomatic congestive heart failure of New York Heart Association Class III or IV.
- •b.Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease.
- •c.Severely impaired lung function as evidenced by:
- •(TLC) <50% predicted, OR (FVC) <50% predicted OR, (DLCO) <40% predicted
- •d.Uncontrolled diabetes/pre-diabetes as defined by fasting serum glucose >5.5mmol/L.
- •e.Active (acute or chronic) or uncontrolled severe infections.
- •f.Liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic p
研究者
相似试验
已完成
不适用
The use of the drug everolimus to reduce hypertrophy of the heart?s left ventricle in kidney transplant recipientson diabetic patients receiving kidney transplantsSurgeryISRCTN93681079San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino) (Italy)30
进行中（未招募）
不适用
Efecto de la inhibición de la diana de rapamicina (mTor) sobre el metabolismo y rendimiento en el ejercicio físico - EXETORPacientes trasplantados renales a los que por indicación clínica se les va a realizar un cambio de un fármaco anti-calcineurínico (Ciclosporina o Tacrolimus) a un inhidor de la diana de rapamicina (everolimus).MedDRA version: 12.1Level: LLTClassification code 10038533Term: Renal transplantEUCTR2009-010541-31-ESServicio Nefrología Hospital Universitario de Bellvitge
招募中
2 期
Clinical study of safety and efficacy of rapamycin topical medication for skin lesions due to tuberous sclerosis complexTuberous sclerosis complexJPRN-UMIN000015114Department of Dermatology Graduate School of Medicine, Osaka University24
进行中（未招募）
不适用
A proof of concept study to test whether talarozole has an effect on hand osteoarthritis in the base of thumb jointOsteoarthritis of the handMusculoskeletal DiseasesArthrosisISRCTN16717773niversity of Oxford44
已完成
2 期
Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complextuberous sclerosis complexJPRN-UMIN000002844Department of Dermatology Graduate School of Medicine, Osaka University21